about
Anticancer properties of propofol-docosahexaenoate and propofol-eicosapentaenoate on breast cancer cellsProdrug Strategies for PaclitaxelDevelopment and Evaluation of a Fluorescent Antibody-Drug Conjugate for Molecular Imaging and Targeted Therapy of Pancreatic CancerThe targeting mechanism of DHA ligand and its conjugate with Gemcitabine for the enhanced tumor therapyStyrene maleic acid micelles as a nanocarrier system for oral anticancer drug delivery - dual uptake through enterocytes and M-cells.2'-Behenoyl-paclitaxel conjugate containing lipid nanoparticles for the treatment of metastatic breast cancerUpdate on taxane development: new analogs and new formulationsPhase I/II study of DHA-paclitaxel in combination with carboplatin in patients with advanced malignant solid tumours.Taxane anticancer agents: a patent perspective.Paclitaxel Nano-Delivery Systems: A Comprehensive Review.Synthesis, Characterization, and In Vitro and In Vivo Evaluations of 4-(N)-Docosahexaenoyl 2', 2'-Difluorodeoxycytidine with Potent and Broad-Spectrum Antitumor Activity.Early investigational tubulin inhibitors as novel cancer therapeutics.Advances in oral delivery of anti-cancer prodrugs.Development and optimization of oil-filled lipid nanoparticles containing docetaxel conjugates designed to control the drug release rate in vitro and in vivo.Lipid-Drug Conjugate for Enhancing Drug Delivery.Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer.Development of Poly Unsaturated Fatty Acid Derivatives of Aspirin for Inhibition of Platelet Function.Chemical modification allows phallotoxins and amatoxins to be used as tools in cell biology.The properties and kinetics of enzymatic reaction in the process of the enzymatic extraction of fish oil.ω-3 Long Chain Polyunsaturated Fatty Acids as Sensitizing Agents and Multidrug Resistance Revertants in Cancer Therapy.Preclinical development of drug delivery systems for paclitaxel-based cancer chemotherapy.
P2860
Q24813316-1B40CFC3-BC4C-4A4B-9541-4537216BE05CQ26745997-C2BDF5B1-D592-402B-9736-54DEFD601656Q28552050-70A7984D-D185-4B5B-94A0-58AF32452B6FQ33976984-8AC32236-7023-4A72-B246-A174E6E07E6AQ35892628-A5D345A6-1140-44E3-9920-B6C8F3DCBE94Q36468079-07616BE2-652C-4C6C-BF55-030431BF1999Q36470377-A6C70020-A55D-45D5-A205-119051F255A5Q36696098-AB8083EB-62F6-4047-A303-F8674E93255EQ37087888-747EE437-EE5A-4EE5-A66B-55315142BFB0Q37250009-4049DE49-2D7A-4A38-ACCC-F1781BE9B27FQ38799790-7A20777A-B4D6-4885-98AE-63E442C1C5F5Q38836161-C9127B19-519F-4774-8612-A2E9A55B0C84Q38862820-8460A0A0-6E9D-4257-8858-6017C0EA8C5FQ38885649-21546914-4D77-4E30-9821-DBCCD83664A0Q39083391-68CBF781-A421-417E-A64D-1D73A1BF1DF7Q41897007-F8CF2476-5428-45FA-BCAF-1F1D10619982Q41990578-ED6B8630-B037-4ECE-BCAE-0CD6A6B0D7F5Q42374014-B0DD11CC-BE1C-4E24-A3CB-97B9E8BA4CCEQ42908878-FEEDAA8B-F2DD-4E9C-B453-F3FCF59E9AA3Q47230140-FBBD4EBB-FC6B-45C3-A7ED-197D6B41E311Q47621457-670DC798-A09F-49CF-9443-BCCBE133EC05
P2860
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Tumor targeting by conjugation of DHA to paclitaxel.
@en
Tumor targeting by conjugation of DHA to paclitaxel.
@nl
type
label
Tumor targeting by conjugation of DHA to paclitaxel.
@en
Tumor targeting by conjugation of DHA to paclitaxel.
@nl
prefLabel
Tumor targeting by conjugation of DHA to paclitaxel.
@en
Tumor targeting by conjugation of DHA to paclitaxel.
@nl
P2093
P1476
Tumor targeting by conjugation of DHA to paclitaxel.
@en
P2093
Anthony FH
Bradley MO
Devanesan P
Donehower RC
Swindell CS
P304
P356
10.1016/S0168-3659(01)00321-2
P407
P577
2001-07-01T00:00:00Z